China Pharma Holdings, Inc. (CPHI) shareholders
Close on Nov 11, 2026Market cap $23.37MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tao Liu | 15,000,000 | 27.30% | 13G (passive) | Dec 28, 2023 |
| Streeterville Capital LLC Joint filing with Streeterville Management LLC (9.99%), John M. Fife (9.99%) | 3,291,872 | 9.99% | 13G (passive) amendment | Jan 12, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CPHI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 125,445 | 0.29% | $82.81K | +112,521 | 0.00% |
| Two Sigma Securities, LLC | 35,666 | 0.08% | $23.54K | New | 0.00% |
| Renaissance Technologies LLC | 15,045 | 0.03% | $9.93K | +3,627 | 0.00% |
| Jane Street Group, LLC | 13,886 | 0.03% | $9.17K | New | 0.00% |
| Ground Swell Capital, LLC | 10,610 | 0.02% | $7.00K | New | 0.01% |
| UBS Group AG | 3,109 | 0.01% | $2.05K | +2,720 | 0.00% |
| EFG International AG | 40 | 0.00% | $26 | – | 0.00% |
| Danske Bank A/S | 1 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 0.5% | 3 / 3 | 0 / 1 | 0M | 0M |
| Q1 2026 | 6 | 0M | 0.1% | 2 / 1 | 1 / 1 | 0M | 0M |
| Q4 2025 | 5 | 0M | 0.1% | 2 / 1 | 1 / 2 | 0M | 0M |
| Q3 2025 | 5 | 0M | 0.1% | 2 / 1 | 1 / 2 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0.3% | 5 / 0 | 0 / 0 | 0M | 0M |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Zhilin Li CEO & Interim CFO, Director, 10% owner | Sep 29, 2023 | Award | +13,757,063 | $0.14 | $1.93M | 15,138,063 |
| Zhilin Li CEO & Interim CFO, Director, 10% owner | Sep 9, 2021 | Award | +1,760,000 | $0.67 | $1.18M | 13,810,000 |
| Zhilin Li CEO and interim CFO, Director, 10% owner | Dec 23, 2020 | Award | +2,000,000 | – | – | 12,050,000 |
| Frank Waung Chief Financial Officer | Apr 28, 2012 | Award | +100,000 | – | – | 138,415 |
| Frank Waung Chief Financial Officer | May 25, 2011 | Award | +25,000 | – | – | 38,415 |
| Zhilin Li President and CEO, Director, 10% owner | May 25, 2011 | Award | +50,000 | – | – | 10,050,000 |
| Frank Waung Chief Financial Officer | Dec 13, 2010 | Award | +6,863 | – | – | 13,415 |
| Frank Waung Chief Financial Officer | Nov 15, 2010 | Option exercise | +4,052 | – | – | 6,552 |
| Heung Mei Tsui Director, 10% owner | Feb 9, 2010 | Award | −1,500,000 | $3.00 | $4.50M | 9,312,651 |
| Heung Mei Tsui Director, 10% owner | Nov 26, 2007 | Award | −4,465,734 | $1.52 | $6.79M | 10,812,651 |
| Zhilin Li President and CEO, Director, 10% owner | Sep 13, 2006 | Award | +10,000,000 | – | – | 10,000,000 |
| Heung Mei Tsui Director, 10% owner | Sep 13, 2006 | Award | −10,000,000 | – | – | 15,278,385 |
| Heung Mei Tsui Director, 10% owner | May 16, 2006 | Award | +4,723,056 | – | – | 25,278,385 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of China Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 333,183 shares on Oct 9, 2026 over the last 90 days.
See a number that looks wrong?